These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

316 related items for PubMed ID: 9211570

  • 1. Combination therapy using moclobemide with tricyclic and tetracyclic antidepressants to treat therapy-resistant depression.
    König F, Wolfersdorf M.
    Pharmacopsychiatry; 1997 May; 30(3):93-6. PubMed ID: 9211570
    [Abstract] [Full Text] [Related]

  • 2. [Treatment of depression using MAO-A inhibitors: an open study of a direct switch from moclobemide to tri-/tetracyclic antidepressants].
    Becker T, Struck M, Laux G.
    Psychiatr Prax; 1989 Aug; 16 Suppl 1():44-7. PubMed ID: 2685856
    [Abstract] [Full Text] [Related]

  • 3. Trimipramine and maprotiline plasma levels during combined treatment with moclobemide in therapy-resistant depression.
    König F, Wolfersdorf M, Löble M, Wössner S, Hauger B.
    Pharmacopsychiatry; 1997 Jul; 30(4):125-7. PubMed ID: 9271778
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The efficacy of reversible monoamine oxidase inhibitors in depressive illness.
    Roth M, Guelfi JD.
    Can J Psychiatry; 1992 Sep; 37 Suppl 1():18-24. PubMed ID: 1394027
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Reversible monoamine oxidase-A inhibitors in resistant major depression.
    Nolen WA, Hoencamp E, Bouvy PF, Haffmans PM.
    Clin Neuropharmacol; 1993 Sep; 16 Suppl 2():S69-76. PubMed ID: 8313400
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A controlled double-blind trial of moclobemide and imipramine in the treatment of depression.
    Kok LP, Tsoi WF.
    Singapore Med J; 1995 Feb; 36(1):38-40. PubMed ID: 7570133
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Treatment of depressions resistant to tricyclic antidepressants, related drugs or MAO-inhibitors by lithium addition: review of the literature.
    Schöpf J.
    Pharmacopsychiatry; 1989 Sep; 22(5):174-82. PubMed ID: 2682691
    [Abstract] [Full Text] [Related]

  • 14. Controlled comparison of RO 11-1163 (moclobemide) and placebo in the treatment of depression.
    Botte L, Evrard JL, Gilles C, Stenier P, Wolfrum C.
    Acta Psychiatr Belg; 1992 Sep; 92(6):355-69. PubMed ID: 1345409
    [Abstract] [Full Text] [Related]

  • 15. [Psychometric findings in treatment using the selective MAO-A inhibitors moclobemide and maprotiline].
    Classen W.
    Psychiatr Prax; 1989 Aug; 16 Suppl 1():41-3. PubMed ID: 2587675
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Acute therapy of depression.
    Bech P.
    J Clin Psychiatry; 1993 Aug; 54 Suppl():18-27; discussion 28. PubMed ID: 8253702
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Clinical, biochemical and psychometric findings with the new MAO-A-inhibitors moclobemide and brofaromine in patients with major depressive disorder.
    Laux G, Classen W, Sofic E, Becker T, Riederer P, Lesch KP, Struck M, Beckmann H.
    J Neural Transm Suppl; 1990 Aug; 32():189-95. PubMed ID: 2089089
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.